Post-earnings recap
Reported
Tue, Oct 29, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Corvus Pharmaceuticals reported a loss of $0.37 per share, but there were no revenue figures provided. The stock reacted negatively, declining by 3.28%. Investors may be concerned about the lack of guidance and clarity on future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.